62 results about "Osteoclast cell differentiation" patented technology

The invention provides an application of bifidobacterium animalis subsp. Lactis CP-9 in preparation of a product for promoting bone growth and development or improving bone health. Long-term research and a large number of experiments show that the bifidobacterium animalis subsp. Lactis CP-9 can improve the bone volume fraction, the bone trabecula thickness, the bone density and the bone volume of an organism, and can also effectively improve the growth hormone level and the insulin-like growth factor 1 level, so that bone growth and development are promoted. Meanwhile, the bifidobacterium animalis subsp. Lactis CP-9 can effectively improve the N-terminal propeptide level, osteocalcin level, bone morphogenetic protein level and osteoprotectin level of I-type procollagen in a body, and remarkably reduce the amino-terminal peptide level of the I-type collagen and the ligand level of nuclear factor kappa B receptor activating factor, so that osteoblast differentiation is promoted, osteoclast differentiation is inhibited, and osteoclast differentiation is inhibited. Furthermore, bone formation is promoted, bone resorption is inhibited, bone metabolism is improved, and finally the effect of improving bone health is achieved.

The invention relates to the technical field of medicine, in particular to application of beta-hydroxybutyric acid in preparation of medicine for preventing and / or treating osteoporosis, the osteoporosis comprises postmenopausal osteoporosis and diabetic osteoporosis due to estrogen deficiency, the administration concentration of the beta-hydroxybutyric acid is 150mM, and the administration concentration of the beta-hydroxybutyric acid is 10mM. According to the application of the beta-hydroxybutyric acid in preparing the medicine for inhibiting osteoclast differentiation or osteoclast formation, the beta-hydroxybutyric acid inhibits osteoclast precursor cells from being differentiated into osteoclasts, and the administration concentration of the beta-hydroxybutyric acid is 10 mM; the invention proves that the beta-hydroxybutyric acid improves bone microstructures of OVX mice and db / db mice, inhibits osteoclast differentiation and reduces bone resorption, and provides a new target for prevention and treatment of osteoporosis.

The invention relates to application of an oroxylum indicum flavone extract in tumor-induced bone destruction, and relates to the field of biological medicines. The oroxylum indicum flavone extract comprises at least one of oroxylum indicum A and oroxylum indicum B, can inhibit tumor-induced osteoclast generation, can be used as a tumor-induced osteoclast differentiation inhibitor drug, and is used for treating tumor-induced bone destruction osteoclast activity abnormity diseases.

The invention provides a polyketone compound and application thereof in preparation of an osteoclast differentiation inhibitor, and relates to the technical field of marine natural products. The compound is obtained by separation and purification from a fermentation culture of a marine fungus talaromyces sp. GMIMD 02524 (the preservation number is GDMCC No. 66968), the compound is named as talaromyces furanone A, and the structure of the compound is as shown in the formula (I) in the specification. The compound can effectively inhibit RANKL-induced osteoclast differentiation by inhibiting an NF-kappa B signal channel in vitro, and has no obvious cytotoxicity at an effective concentration. Therefore, the compound talaromyfuranone A can be used for developing medicines for preventing and treating osteoclast-related osteolytic diseases such as osteoporosis and the like, and has a good application prospect.

The invention discloses application of a compound with a benzo-aza structure in preparation of a medicine for inhibiting osteoclast formation, the structure of the compound is shown as a formula (1), and R substituent is one of H, OCH3, Br, F and i-Pr. Cell experiments prove that the compound with the benzo-aza structure has a remarkable inhibiting effect on RANKL-induced osteoclast differentiation and marker gene expression, can be used as a candidate medicine which is novel in structure and is used for inhibiting osteoclast formation, and is used for targeting osteoclast to treat osteoporosis related diseases.

The present invention relates to a ginseng peptide and a preparation method and application thereof, belonging to the field of biotechnology. The present invention provides a ginseng peptide, wherein the ginseng peptide comprises a characteristic peptide having an amino acid sequence of at least one of LY, MM, LR, AP, LAR, RLDFR, SALAFR, LLLLGH and LLLLLHG. The present invention obtains ginseng peptides by treating fermented ginseng residue, and identifies the characteristic peptides containing the amino acid sequences of LY, MM, LR, AP, LAR, RLDFR, SALAFR, LLLLGH and LLLLLHG in the ginseng peptides by HPLC-MS / MS. The present invention confirms through experiments that ginseng peptides and fermented ginseng hydrolysates containing ginseng peptides have excellent efficacy in inhibiting the differentiation of bone marrow mononuclear cells into osteoclasts, can improve hormone-induced osteoporosis, and can be applied to products for improving osteoporosis and its related symptoms.

The present invention belongs to the field of medicine and relates to the use of benzothiazinone vinylidene indene compounds in the preparation of osteoclast differentiation inhibitors. The present invention uses tartrate-resistant acid phosphatase (TRAP) staining and reverse transcription real-time fluorescence quantitative polymerase chain reaction (RT-qPCR) technology to confirm for the first time that this series of compounds can significantly inhibit RANKL-induced osteoclast differentiation and the formation of multinucleated osteoclasts, and are non-cytotoxic at concentrations of 5μM and below. Based on these findings, the benzothiazinone vinylidene indene compounds provided by the present invention can be used as candidate drug molecules for novel osteoclast differentiation inhibitors, for the prevention and / or treatment of bone metabolic diseases caused by excessive activation of osteoclasts, such as osteoporosis, periprosthetic bone dissolution, tumor metastasis bone destruction, and rheumatoid arthritis.

The present application relates to the pharmaceutical use of 4-[9-(6-aminopurine)]-2(S)-hydroxybutyric acid methyl ester, in particular to its use in the preparation of a medicament for preventing and / or treating diseases associated with abnormal osteoclast activity. It has been found that 4-[9-(6-aminopurine)]-2(S)-hydroxybutyric acid methyl ester has a significant inhibitory effect on osteoclast differentiation, and intra-articular injection of 4-[9-(6-aminopurine)]-2(S)-hydroxybutyric acid methyl ester has a therapeutic effect on MIA-induced osteoarthritis. Therefore, 4-[9-(6-aminopurine)]-2(S)-hydroxybutyric acid methyl ester has the prospect of being developed into a therapeutic drug for diseases associated with abnormal osteoclast activity.

The present invention discloses a PP-BST 3‑x The invention relates to an implant and its preparation method and application, which belongs to the field of medical material technology. The invention constructs oxygen vacancies (BST) on the surface of strontium ion-doped barium titanate. 3‑x ), under ultrasonic conditions, the internal electron movement of the material is enhanced, making the electron-hole separation easier, thereby accelerating the reaction of electrons with surrounding substances and improving the efficiency of ROS generation. And the PP-BST prepared by the present invention 3‑x On the one hand, the implant can polarize macrophages through electrical potential and inhibit inflammation; on the other hand, it can regulate Sr release through ultrasound, thereby inhibiting osteoclast differentiation in an infected environment, achieving dual-pathway osteogenesis, and improving the high osteoclast environment brought about by the bacterial microenvironment while inhibiting bacteria, thereby promoting bone regeneration, accelerating bone healing ability, and reducing patient recovery time.

The invention belongs to the technical field of biological medicines, discloses application of an STK26 gene in preparation of medicines for treating or preventing osteoporosis, and particularly relates to application of STK26 protein or a coding gene thereof in preparation of medicines for treating osteoporosis. According to the present invention, osteoclast differentiation is inhibited by knocking out the STK26 gene so as to treat osteoporosis, osteoclast differentiation can be promoted by overexpressing the specific STK26 protein and the encoded gene thereof so as to aggravate osteoporosis, and osteoporosis can be alleviated by specifically knocking out the STK26 in an ovariectomized osteoporosis mouse model and an age-related osteoporosis mouse model; overexpression of the STK26 recombinant protein can aggravate osteoporosis, and the STK26 protein and the coding gene thereof can be used as targets of clinical drug treatment, and have good prospects in screening and preparation of drugs for treating osteoporosis.

To provide a novel Lactobacillus paracasei strain with bone regeneration effects, and pharmaceutical and food compositions containing the same. [Solution] The present invention relates to a novel Lactobacillus paracasei L-30 and its uses, and more particularly to Lactobacillus paracasei L-30 (KCTC16035BP) which has the ability to promote the differentiation or formation of osteoblasts, the ability to suppress the differentiation or formation of osteoclasts, and the ability to promote immune activity, and which can regenerate bone, and to a pharmaceutical composition for the treatment or prevention of bone diseases containing the same.

The invention provides a novel hydroxyl indanone compound and application thereof in preparation of an osteoclast differentiation inhibitor, and belongs to the field of marine natural products. The invention discloses a hydroxyl indanone compound which is named as (R)-3, 4-dihydroxy-2, 3-dihydro-1H-indan-1-one, the structural formula of the hydroxyl indanone compound is shown as a formula (I), the hydroxyl indanone compound has a remarkable inhibition effect on LPS (Lipopolysaccharide) induced NF-kappa B luciferase, can remarkably inhibit RANKL induced bone marrow macrophages from being differentiated into osteoclasts at the concentration of 20 mu M or below, and does not generate cytotoxicity at the concentration of 20 mu M or below. The hydroxyindanone compound can be used as an osteoclast differentiation inhibitor medicine and is used for preventing and treating osteolytic diseases such as osteoporosis. # imgabs0 #

The present application relates to the technical field of medicine, and more particularly to the application of beta-hydroxybutyric acid in the preparation of a drug for preventing and / or treating osteoporosis, including postmenopausal osteoporosis due to estrogen deficiency and diabetic osteoporosis, wherein the concentration of the beta-hydroxybutyric acid is 150 mM, the application of beta-hydroxybutyric acid in the preparation of a drug for inhibiting the differentiation of osteoclasts or inhibiting the formation of osteoclasts, wherein the beta-hydroxybutyric acid inhibits the differentiation of osteoclast precursor cells into osteoclasts, and the concentration of the beta-hydroxybutyric acid is 10 mM; the present application proves that beta-hydroxybutyric acid improves the bone microstructure of OVX mice and db / db mice, inhibits the differentiation of osteoclasts, and reduces bone resorption, thereby providing a new target for the prevention and treatment of osteoporosis.

To provide a novel osteoclast differentiation inhibitor.SOLUTION: The osteoclast differentiation inhibitor comprises a compound represented by the general formula (I) in the figure, or a pharmaceutically acceptable salt, glycoside or ester thereof: (In the formula, R1, R2 and R3 are the same or different and each represent a linear or branched alkyl group having 1 to 6 carbon atoms, and m represents 0, 1, or 2.)SELECTED DRAWING: None

The invention discloses an application of a branched ketonic acid dehydrogenase kinase (BCKDK) inhibitor in preparation of a medicine for preventing and treating osteoporosis. The invention finds that BCKDK can inhibit osteoblast differentiation and reduce the expression of endogenous BCKDK in osteogenic precursor cells so as to promote osteoblast differentiation; a small molecule compound inhibitor BT2 (3, 6-dichloro-2-benzothiophene carboxylic acid) of BCKDK promotes osteoblast differentiation of ovariectomized mice, inhibits osteoclast differentiation, reduces ovariectomized mouse bone loss and increases bone mass. According to the invention, the BCKDK inhibitor is proposed for the first time to be capable of promoting osteoblast differentiation, inhibiting osteoclast differentiation and increasing body bone mass by reducing BCKDK expression or inhibiting BCKDK protein biological functions, and has the effect of preventing and treating osteoporosis.

The present invention relates to a composition for the prevention, improvement, or treatment of bone diseases comprising a complex extract composed of deer antler, white soybean, Angelica gigas, and Cnidium officinale as an active ingredient. The complex extract has the effect of promoting the differentiation of bone-forming osteoblasts and bone formation, and promoting the differentiation of bone-resorbing osteoclasts and inhibiting bone resorption at an in vitro level. Furthermore, since it promotes fracture union in a fracture-induced animal model and exhibits a significant recovery effect on fractures, it can be usefully utilized as a health functional food or pharmaceutical related to bone diseases.

This invention relates to the application of 5-(tetradecoxy)-2-furoic acid (TOFA) in the preparation of drugs that inhibit osteoclast differentiation and function. Using a RANKL-induced mouse bone marrow macrophage osteoclast differentiation model, experiments demonstrated that TOFA can effectively inhibit osteoclast differentiation and function by inhibiting ROS and downregulating the expression of key osteoclast differentiation and function proteins such as Nfatc1, Src, and Ctsk. Furthermore, TOFA at concentrations of 40 μM and below showed no significant cytotoxicity, proving that TOFA can serve as a candidate compound for developing drugs that inhibit osteoclast differentiation and function, and for treating diseases caused by excessive activation of osteoclasts, thus possessing significant clinical application value. Additionally, by constructing a mouse ovariectomized osteoporosis model, the preventive and therapeutic effects of TOFA on estrogen-deficiency-induced osteoporosis were demonstrated.

The invention discloses application of a migration body in preparation of a medicine for inhibiting osteoclast differentiation or promoting osteogenesis. By optimizing cell culture conditions, the secretion amount of the migration body is remarkably increased, large-scale preparation can be realized, and the production cost is greatly reduced. According to the invention, active components in the migration body are enriched through pressure stimulation, so that the migration body has a more excellent effect of promoting bone defect repair. In addition, by utilizing the larger size and stable membrane structure of the migration body, the in-vivo residence time is prolonged, and the long-acting repair of single-time administration is realized, so that the problems of long-acting property and clinical transformation are solved. The migration body disclosed by the invention has a wide application prospect in the field of bone defect repair.

The present invention relates to a pharmaceutical composition containing Cbfβ (Core-binding factor subunit beta) expressing vascular smooth muscle cells or a culture fluid thereof as an active ingredient for the prevention or treatment of age-related diseases. It has been found that inhibition of Cbfβ expression in vascular smooth muscle cells promotes vascular calcification and osteoclast differentiation and that the culture fluid of Cbfβ-expressing vascular smooth muscle cells inhibits osteoclast differentiation. Thus, the composition can be advantageously utilized as a pharmaceutical composition for the prevention, treatment, alleviation, or diagnosis of age-related diseases.

The present invention provides an application of animal Bifidobacterium lactis subspecies CP-9 in the preparation of a product that promotes bone growth and development or improves bone health. After long-term research and a large number of experiments, the present invention found that animal Bifidobacterium lactis subspecies CP-9 can improve the body's bone volume fraction, trabecular thickness, bone density and bone mass, and can also effectively increase the level of growth hormone and insulin-like growth factor 1, thereby promoting bone growth and development. At the same time, animal Bifidobacterium lactis subspecies CP-9 can effectively increase the level of type I procollagen N-terminal propeptide, osteocalcin level, bone morphogenetic protein level, and osteoprotegerin level in the body, and significantly reduce the level of type I collagen amino-terminal peptide and nuclear factor κB receptor activator ligand level, thereby promoting osteoblast differentiation, inhibiting osteoclast differentiation, and then promoting bone formation, inhibiting bone resorption, improving bone metabolism, and ultimately achieving the effect of improving bone health.

The invention discloses a drug for combined treatment of breast cancer bone metastasis, the drug comprises two active components, namely a first active component and a second active component, the first active component is Bufalin and its pharmaceutically acceptable salt, prodrug and derivative, and the second active component is RANKL targeted drug; bufalin and a derivative thereof are combined with an RANKL targeted drug for use, the Bufalin and the derivative thereof are synergistically complementary, and the Bufalin is used for regulating and controlling a tumor microenvironment, reducing secretion of high bone metastatic breast cancer cells HMGB1 and inhibiting differentiation of mononuclear / macrophages in bone marrow to osteoclasts, so that occurrence and development of breast cancer bone metastasis are inhibited; the RANKL targeted drug can specifically block an OPG / RANK / RANKL signal channel, inhibit osteoclast activation, reduce bone destruction and block vicious circle of bone metastasis; when the two active ingredients are combined for use, the effect of inhibiting breast cancer bone metastasis is obviously better than that of single use of any active ingredient, the occurrence of breast cancer bone metastasis can be effectively prevented and delayed, the progress of bone metastasis focus is controlled, and the occurrence risk of bone related events is reduced.

The invention belongs to the technical field of biological medicines, and particularly provides application of Schwann cell exosomes in preparation of osteoclast differentiation resisting medicines. Firstly, a Schwann cell and osteoclast precursor cell co-incubation experiment proves that Schwann cells inhibit osteoclast differentiation through exosomes. Then miRNA sequencing analysis is conducted on Schwann cell exosomes, then a PTEN / AKT signal channel is screened out, and experiments such as TRAP dyeing, RT-qPCR and WB are conducted on the cell molecule level to prove that SC-EXO inhibits osteoclast differentiation through the PTEN / AKT signal channel; meanwhile, through in-vivo experiments, the inhibition effect of SC-EXO on the osteoclast activity of ovarian-removed mice through a PTEN / AKT signal channel is determined. Therefore, the Schwann cell exosome can be used as an osteoclast differentiation inhibitor drug, and can be used as an osteoclast differentiation inhibitor for treating related diseases.

The application discloses a furan coumarin compound and application thereof in preparation of a drug for treating osteoporosis, and belongs to the technical field of drug research and development. 50 The furan coumarin compound has an IC of 37.86 nM, has no obvious cytotoxicity and systemic toxicity, can inhibit a key path of RANKL-induced osteoclast differentiation, and can be used for preparing the drug for treating osteoporosis.

A Lactobacillus paracasei L-30 strain deposited under Accession Number KCTC16035BP has ability to promote osteoblast differentiation or formation, inhibiting osteoclast differentiation or formation, and enhancing immune activity, thereby enabling bone regeneration. A pharmaceutical composition including the Lactobacillus paracasei L-30 strain, a lysate thereof, a culture thereof, an extract thereof, and / or a fraction of the extract may be used for treating or preventing bone diseases.

The invention discloses a PP-BST3-x implant as well as a preparation method and application thereof, and belongs to the technical field of medical materials. According to the method, oxygen vacancies (BST3-x) are constructed on the surface of strontium ion doped barium titanate, so that electron movement in the material is enhanced under an ultrasonic condition, electron holes are easier to separate, the reaction between electrons and surrounding substances is accelerated, and the ROS generation efficiency is improved. In addition, according to the PP-BST3-x implant prepared by the invention, on one hand, macrophages can be polarized through potentials, so that inflammation is inhibited; on the other hand, Sr release can be adjusted through ultrasound, then osteoclast differentiation in the infection environment is inhibited, double-path osteogenesis is achieved, the high osteoclast environment brought by the bacterial microenvironment is improved while bacteria are inhibited, the bone regeneration speed is increased, the bone healing capacity is accelerated, and the recovery time of a patient is shortened.

The present invention relates to a group of anti-osteoporosis compounds and their applications. These compounds can upregulate OPG expression, inhibit inflammatory pathway activation, inhibit osteoclast differentiation or bone resorption, and promote osteoblast differentiation or bone formation; and have high oral bioavailability and anti-osteoporosis activity.

The invention provides a novel compound for inhibiting osteoclast differentiation and preparation and application thereof, and belongs to the technical field of chemical drugs. Cell in-vitro experiments prove that the compound provided by the invention has a significant inhibition effect on osteoclast differentiation induced by RANKL and inflammatory factor TNF-alpha stimulation, and does not have cytotoxicity, so that the compound can be used as a potential drug with a novel structure for inhibiting osteoclast-mediated bone resorption; the pharmaceutical composition is used for treating osteoporosis and inflammatory osteolytic diseases.

The invention relates to an application of 5-(tetradecyloxy)-2-furoic acid in preparation of a medicine for inhibiting osteoclast differentiation and function, an RANKL-induced mouse bone marrow macrophage osteoclast differentiation model is adopted, and experiments prove that TOFA can inhibit osteoclast differentiation and function of osteoclast by inhibiting ROS and down-regulating expression of osteoclast differentiation and function key proteins such as Nfatc1, Src and Ctsk. The application has the advantages that the osteoclast differentiation and functions can be effectively inhibited, the TOFA with the concentration of 40 mu M or below has no obvious cytotoxicity, and the TOFA can be used as a candidate compound for researching and developing the medicines for inhibiting the osteoclast differentiation and the functions, can be used for treating diseases caused by overexpression of the osteoclast, and has important clinical application value; a mouse ovariectomized osteoporosis model is constructed, and the prevention and treatment effect of TOFA on osteoporosis caused by estrogen deficiency is proved.